December 25, 2014
Sysmex Launches the New “Automated Hematology Analyzer XN-L series,” a Compact Model in the XN Family for the Hematology Field
Aimed at Expanding Market Share in Emerging Markets
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) is launching a new product for the hematology field, the automated hematology analyzer XN-L series.
By augmenting the Company’s lineup with the compact XN-L series, which delivers performance similar to or the same as the XN-Series
1, Sysmex’s flagship model, Sysmex aims to better meet the diverse needs of customers centered in emerging markets.
In recent years, rapid rates of economic growth in emerging markets have been prompting the development of healthcare infrastructures. This factor, plus an increasing awareness of health and healthcare, are spurring demand for medical care and testing. At the same time, healthcare needs in advanced countries are growing more diverse, owing to efforts to curtail costs and respond to aging populations, as well as to making inroads in preventive medicine and personalized medicine.
Since the time of its establishment, Sysmex has concentrated on its mainstay field of hematology, which involves the analysis of red blood cells, white blood cells, platelets and other components of blood. Through these efforts, the Company has acquired the leading share of the global hematology market.
We launched our flagship model, the XN series, in 2011, striving to enhance clinical value by providing a low-WBC mode
2 and body fluid mode
3, as well as providing reticulocyte hemoglobin equivalent
4.
We are now launching the automated hematology analyzer XN-L series as a compact model in the XN family.
While carrying forward the functionality and operability that have earned the XN series a strong reputation throughout the world, we have increased this model’s compactness by such means as internalizing the pneumatic power source and miniaturizing detectors. The result is one of the most compact instruments in its class that, in addition to five-part white blood cell differentiation, conducts automated reticulocyte analysis using the fluorescent flow cytometry method and is equipped with a body fluid mode. As well as being compact, the XN-L series offers high levels of performance and operability, allowing it to meet a diverse range of needs. Aimed primarily for use in small and medium-sized healthcare facilities in advanced countries and in emerging markets, the XN-L series is also suited for emergency laboratories at large-scale institutions that have already adopted the XN series.
The new series is also compatible with the Sysmex Network Communication System (SNCS
®5), which allows online monitoring of operating conditions for the instrument. This function enables real-time external quality control, automatic monitoring of instrument conditions and web-based information delivery, helping to pre-empt sudden malfunctions.
We also anticipate demand centered on emerging markets for flagging the change in shape of blood cells that occurs in cases of malaria, one of the world’s three most deadly infectious diseases.
Going forward, Sysmex aims to meet increasingly sophisticated needs in emerging markets, including China and other parts of Asia, that are slated for further growth and experiencing increasing levels of competition. We also aim to contribute to the development of healthcare by providing high-value-added testing.
New Product Overview
Name: Automated Hematology Analyzer XN-L series
Models:
HOME 
